Pfizer is suspending production at its Hospira sterile injectables plant in Rocky Mount, North Carolina, ahead of Hurricane Florence.
Cadila's Liva subsidiary was hit with a Form 483 by the FDA following an inspection of its plant in Vadodara, India.
Ei, a North Carolina CDMO that was hit with a warning letter, has shut its doors as its parent company declared bankruptcy.
No production or safety problems were found at the other 45 vaccine manufacturers in China, the country's drug regulator says.
Analysts are handicapping Teva's chance of getting its migraine drug candidate approved next week given issues at the plant that will produce it.
The deal relieves Novartis of a troubled franchise while boosting buyer Aurobindo to the second-largest generics player by prescriptions in the U.S.
A hospital-backed group, Civica Rx intends to manufacture or contract the production of 14 drugs that are in chronic supply.
ADMA Biologics has its ducks in order to move forward with specialized plasma products that were sidelined by manufacturing issues.
CDMO Olon is continuing its expansion binge with a deal to buy an API plant in India that supplies ingredients to Novartis.
The costs for drugmakers to alter supply chains to keep drugs available in the case of a hard Brexit are running into the hundreds of millions of dollars.